<p>澳大利亚市场正处于谨慎阶段，交易者暂停以评估近期的波动性和即将发布的重要财报。对于愿意探索知名股票之外的投资者来说，便士股票——通常代表较小或较新的公司——可以提供引人注目的机会。尽管这个术语的含义有些过时，但当这些股票具备强大的财务基础和增长潜力时，仍然可以提供可观的价值。</p>
<h3>澳大利亚十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.45</td>
<td>A$128.96M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.825</td>
<td>A$51.37M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.88</td>
<td>A$442.63M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.62</td>
<td>A$267.18M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.32</td>
<td>A$1.04B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.785</td>
<td>A$375.56M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.20</td>
<td>A$1.35B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Fleetwood (ASX:FWD)</td>
<td>A$2.57</td>
<td>A$237.93M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GWA Group (ASX:GWA)</td>
<td>A$2.40</td>
<td>A$629.76M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们 ASX 便士股票筛选器中的 411 只股票的完整列表。</p>
<p>以下是筛选器中的一些选择。</p>
<h2>Cobre (ASX:CBE)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Cobre Limited 参与澳大利亚和博茨瓦纳的矿产资源勘探和评估，市值为 A$49.18 百万。</p>
<p><strong>运营：</strong> 公司的收入完全来自勘探活动，金额为 A$0.35 百万。</p>
<p><strong>市值：</strong> A$49.18M</p>
<p>Cobre Limited 专注于在澳大利亚和博茨瓦纳的矿产勘探，尚未产生收入，勘探活动收入为 A$0.35 百万。公司无债务，但面临挑战，截止 2025 年 6 月 30 日的年度净亏损为 A$2.12 百万。尽管在过去五年中每年减少亏损 7.9%，但审计师对 Cobre 的财务稳定性表示质疑，认为其持续经营能力存在风险。最近通过股权融资筹集的 A$700 万可能提供短期缓解，但突显了持续的流动性压力和股东稀释的担忧，尽管管理团队经验丰富。</p>
<ul>
<li>点击探索我们在 Cobre 财务健康报告中的详细发现。</li>
<li>通过查看我们的历史业绩报告，获取 Cobre 的历史结果的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d4b0dfcf-6a6c-4bc4-866c-0cddb9ddf808/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d4b0dfcf-6a6c-4bc4-866c-0cddb9ddf808/chart/financial-position-analysis"/></p>
<p>ASX:CBE 财务状况分析截至 2025 年 11 月</p>
<h2>SKS Technologies Group (ASX:SKS)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> SKS Technologies Group Limited 在澳大利亚运营，专注于音频视觉、电气和通信产品及服务的设计、供应和安装，市值为 A$388.86 百万。</p>
<p><strong>运营：</strong> 该公司在照明和音频视觉市场的运营中产生了 A$261.66 百万的收入。</p>
<p><strong>市值：</strong> A$388.86M</p>
<p>SKS Technologies Group 展示了强劲的财务表现，过去一年收益增长 111.8%，超过行业平均水平。公司无债务，保持健康的资产负债表，短期资产超过短期和长期负债。SKS 的股本回报率高达 57.2%，反映出对股东资金的高效管理。然而，近期内部人士的大量抛售可能对潜在投资者构成担忧。尽管如此，SKS 宣布截至 2025 年 6 月 30 日的每股派息 A$0.05，表明其对持续盈利和现金流生成能力的信心，尽管每周波动稳定。</p>
<ul>
<li>解锁我们对 SKS Technologies Group 股票分析的全面见解，查看此财务健康报告。</li>
<li>查看我们的增长表现报告，以获取 SKS Technologies Group 未来的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/671ce2bc-92e2-4b23-9582-6699d498e1cc/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/671ce2bc-92e2-4b23-9582-6699d498e1cc/chart/financial-position-analysis"/></p>
<p>ASX:SKS 财务状况分析截至 2025 年 11 月</p>
<h2>Starpharma Holdings (ASX:SPL)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Starpharma Holdings Limited 是一家生物制药公司，专注于全球药物和医疗保健应用的树枝状聚合物技术的研究、开发和商业化，市值为 A$175.65 百万。</p>
<p><strong>运营：</strong> 该公司通过树枝状聚合物的发现、开发和商业化产生了 A$5.85 百万的收入。</p>
<p><strong>市值：</strong> A$175.65M</p>
<p>Starpharma Holdings 的市值为 A$175.65 百万，正在利用其树枝状聚合物技术在生物制药领域中航行。尽管尚未盈利且股价波动较大，但 Starpharma 的短期资产超过其负债，提供了一定的财务稳定性。最近与 Genentech 和 Radiopharm 的合作突显了战略伙伴关系，这可能通过里程碑付款和特许权使用费增强未来的收入来源，尽管当前收入仅为 A$6 百万。管理团队的平均任期相对较短，仅为 1.8 年，表明近期的领导变动可能会影响未来在这一高风险领域的战略方向。</p>
<ul>
<li>通过我们的全面资产负债表健康报告，深入了解 Starpharma Holdings 的复杂性。</li>
<li>通过我们的公司收益预估报告，获取 Starpharma Holdings 的前景和预期表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b323321-8904-4741-a853-0e7a90dcce93/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b323321-8904-4741-a853-0e7a90dcce93/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 11 月，ASX:SPL 的债务与股本历史及分析</p>
<h2>抓住机会</h2>
<ul>
<li>点击此链接访问 411 只 ASX 便士股票的完整范围。</li>
<li>对其他可能性感兴趣？通过投资可靠的分红股票来多样化您的投资组合，以应对潜在的市场波动。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

<p>澳大利亚市场保持谨慎，交易者正在评估波动性和财报。便士股票，通常是较小或较新的公司，提供了引人注目的机会。值得注意的股票包括 Cobre Limited、SKS Technologies Group 和 Starpharma Holdings，它们各自具有独特的财务状况和增长潜力。Cobre 面临流动性挑战，SKS 表现出强劲的财务业绩，而 Starpharma 则在探索树状聚合物技术。投资者可以探索 411 只 ASX 便士股票，以实现多样化和潜在增长</p>

<p>The Australian market is experiencing a cautious phase, with traders pausing to assess recent volatility and upcoming significant earnings reports. For investors willing to explore beyond well-known stocks, penny stocks—typically representing smaller or newer companies—can offer intriguing opportunities. Despite the term's outdated connotations, these stocks can provide substantial value when they possess strong financial foundations and potential for growth.</p>
<div class="lb-trans"><p>澳大利亚市场正处于谨慎阶段，交易者暂停以评估近期的波动性和即将发布的重要财报。对于愿意探索知名股票之外的投资者来说，便士股票——通常代表较小或较新的公司——可以提供引人注目的机会。尽管这个术语的含义有些过时，但当这些股票具备强大的财务基础和增长潜力时，仍然可以提供可观的价值。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亚十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.45</td>
<td>A$128.96M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.825</td>
<td>A$51.37M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.88</td>
<td>A$442.63M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.62</td>
<td>A$267.18M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.32</td>
<td>A$1.04B</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.785</td>
<td>A$375.56M</td>
<td>✅ 5 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.20</td>
<td>A$1.35B</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Fleetwood (ASX:FWD)</td>
<td>A$2.57</td>
<td>A$237.93M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>GWA Group (ASX:GWA)</td>
<td>A$2.40</td>
<td>A$629.76M</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.45</td>
<td>A$128.96M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.825</td>
<td>A$51.37M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.88</td>
<td>A$442.63M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.62</td>
<td>A$267.18M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.32</td>
<td>A$1.04B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.785</td>
<td>A$375.56M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.20</td>
<td>A$1.35B</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Fleetwood (ASX:FWD)</td>
<td>A$2.57</td>
<td>A$237.93M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GWA Group (ASX:GWA)</td>
<td>A$2.40</td>
<td>A$629.76M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 411 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们 ASX 便士股票筛选器中的 411 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是筛选器中的一些选择。</p>
</div><h2>Cobre (ASX:CBE)</h2>
<div class="lb-trans"><h2>Cobre (ASX:CBE)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Cobre Limited is involved in the exploration and evaluation of mineral properties in Australia and Botswana, with a market cap of A$49.18 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cobre Limited 参与澳大利亚和博茨瓦纳的矿产资源勘探和评估，市值为 A$49.18 百万。</p>
</div><p><strong>Operations:</strong> The company's revenue segment is solely derived from exploration activities, amounting to A$0.35 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入完全来自勘探活动，金额为 A$0.35 百万。</p>
</div><p><strong>Market Cap:</strong> A$49.18M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$49.18M</p>
</div><p>Cobre Limited, focused on mineral exploration in Australia and Botswana, remains pre-revenue with A$0.35 million from exploration activities. The company is debt-free but faces challenges with a net loss of A$2.12 million for the year ending June 30, 2025. Despite reducing losses by 7.9% annually over five years, Cobre's financial stability is questioned by its auditors regarding its ability to continue as a going concern. Recent capital raises totaling A$7 million through equity offerings may provide short-term relief but highlight ongoing liquidity pressures and shareholder dilution concerns amidst an experienced management team.</p>
<div class="lb-trans"><p>Cobre Limited 专注于在澳大利亚和博茨瓦纳的矿产勘探，尚未产生收入，勘探活动收入为 A$0.35 百万。公司无债务，但面临挑战，截止 2025 年 6 月 30 日的年度净亏损为 A$2.12 百万。尽管在过去五年中每年减少亏损 7.9%，但审计师对 Cobre 的财务稳定性表示质疑，认为其持续经营能力存在风险。最近通过股权融资筹集的 A$700 万可能提供短期缓解，但突显了持续的流动性压力和股东稀释的担忧，尽管管理团队经验丰富。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Cobre's financial health report.</li>
<li>Gain insights into Cobre's historical outcomes by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 Cobre 财务健康报告中的详细发现。</li>
<li>通过查看我们的历史业绩报告，获取 Cobre 的历史结果的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d4b0dfcf-6a6c-4bc4-866c-0cddb9ddf808/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/d4b0dfcf-6a6c-4bc4-866c-0cddb9ddf808/chart/financial-position-analysis"/></p>
<p>ASX:CBE Financial Position Analysis as at Nov 2025</p>
<div class="lb-trans"><p>ASX:CBE 财务状况分析截至 2025 年 11 月</p>
</div><h2>SKS Technologies Group (ASX:SKS)</h2>
<div class="lb-trans"><h2>SKS Technologies Group (ASX:SKS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> SKS Technologies Group Limited operates in Australia, focusing on the design, supply, and installation of audio visual, electrical, and communication products and services with a market cap of A$388.86 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> SKS Technologies Group Limited 在澳大利亚运营，专注于音频视觉、电气和通信产品及服务的设计、供应和安装，市值为 A$388.86 百万。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$261.66 million from its operations in the lighting and audio-visual markets.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司在照明和音频视觉市场的运营中产生了 A$261.66 百万的收入。</p>
</div><p><strong>Market Cap:</strong> A$388.86M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$388.86M</p>
</div><p>SKS Technologies Group has demonstrated strong financial performance, with earnings growing 111.8% over the past year, surpassing industry averages. The company is debt-free and maintains a healthy balance sheet, with short-term assets exceeding both short- and long-term liabilities. SKS's return on equity is outstanding at 57.2%, reflecting efficient management of shareholder funds. However, significant insider selling in recent months could be a concern for potential investors. Despite this, SKS declared a dividend of A$0.05 per share for the year ended June 30, 2025, indicating confidence in its ongoing profitability and cash flow generation capabilities amidst stable weekly volatility.</p>
<div class="lb-trans"><p>SKS Technologies Group 展示了强劲的财务表现，过去一年收益增长 111.8%，超过行业平均水平。公司无债务，保持健康的资产负债表，短期资产超过短期和长期负债。SKS 的股本回报率高达 57.2%，反映出对股东资金的高效管理。然而，近期内部人士的大量抛售可能对潜在投资者构成担忧。尽管如此，SKS 宣布截至 2025 年 6 月 30 日的每股派息 A$0.05，表明其对持续盈利和现金流生成能力的信心，尽管每周波动稳定。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of SKS Technologies Group stock in this financial health report.</li>
<li>Review our growth performance report to gain insights into SKS Technologies Group's future.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 SKS Technologies Group 股票分析的全面见解，查看此财务健康报告。</li>
<li>查看我们的增长表现报告，以获取 SKS Technologies Group 未来的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/671ce2bc-92e2-4b23-9582-6699d498e1cc/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/671ce2bc-92e2-4b23-9582-6699d498e1cc/chart/financial-position-analysis"/></p>
<p>ASX:SKS Financial Position Analysis as at Nov 2025</p>
<div class="lb-trans"><p>ASX:SKS 财务状况分析截至 2025 年 11 月</p>
</div><h2>Starpharma Holdings (ASX:SPL)</h2>
<div class="lb-trans"><h2>Starpharma Holdings (ASX:SPL)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Starpharma Holdings Limited is a biopharmaceutical company focused on the research, development, and commercialization of dendrimer technology for pharmaceutical and healthcare applications globally, with a market cap of A$175.65 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Starpharma Holdings Limited 是一家生物制药公司，专注于全球药物和医疗保健应用的树枝状聚合物技术的研究、开发和商业化，市值为 A$175.65 百万。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$5.85 million from the discovery, development, and commercialization of dendrimers.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司通过树枝状聚合物的发现、开发和商业化产生了 A$5.85 百万的收入。</p>
</div><p><strong>Market Cap:</strong> A$175.65M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$175.65M</p>
</div><p>Starpharma Holdings, with a market cap of A$175.65 million, is navigating the biopharmaceutical landscape with its dendrimer technology. Despite being unprofitable and having volatile share prices, Starpharma's short-term assets surpass its liabilities, providing some financial stability. Recent collaborations with Genentech and Radiopharm highlight strategic partnerships that could enhance future revenue streams through milestone payments and royalties, although current revenues are limited at A$6 million. The management team has a relatively short average tenure of 1.8 years, suggesting recent leadership changes which might influence strategic direction moving forward in this high-risk sector.</p>
<div class="lb-trans"><p>Starpharma Holdings 的市值为 A$175.65 百万，正在利用其树枝状聚合物技术在生物制药领域中航行。尽管尚未盈利且股价波动较大，但 Starpharma 的短期资产超过其负债，提供了一定的财务稳定性。最近与 Genentech 和 Radiopharm 的合作突显了战略伙伴关系，这可能通过里程碑付款和特许权使用费增强未来的收入来源，尽管当前收入仅为 A$6 百万。管理团队的平均任期相对较短，仅为 1.8 年，表明近期的领导变动可能会影响未来在这一高风险领域的战略方向。</p>
</div><ul>
<li>Navigate through the intricacies of Starpharma Holdings with our comprehensive balance sheet health report here.</li>
<li>Gain insights into Starpharma Holdings' outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的全面资产负债表健康报告，深入了解 Starpharma Holdings 的复杂性。</li>
<li>通过我们的公司收益预估报告，获取 Starpharma Holdings 的前景和预期表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b323321-8904-4741-a853-0e7a90dcce93/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/2b323321-8904-4741-a853-0e7a90dcce93/chart/debt-equity-history-analysis"/></p>
<p>ASX:SPL Debt to Equity History and Analysis as at Nov 2025</p>
<div class="lb-trans"><p>截至 2025 年 11 月，ASX:SPL 的债务与股本历史及分析</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Access the full spectrum of 411 ASX Penny Stocks by clicking on this link.</li>
<li>Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接访问 411 只 ASX 便士股票的完整范围。</li>
<li>对其他可能性感兴趣？通过投资可靠的分红股票来多样化您的投资组合，以应对潜在的市场波动。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

3 只市值低于 4 亿澳元的 ASX 便士股值得关注